| 10/27/2026 5:51 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/22/2026 6:10 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/08/2026 6:12 AM | AstraZeneca (901832) Issuer Sharma Mani (2122411) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/05/2026 6:35 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/02/2026 5:58 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/01/2026 10:40 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/01/2026 10:32 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/29/2026 5:41 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/23/2026 5:01 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/21/2026 6:04 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/21/2026 5:50 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Get the Latest News and Ratings for AZNCF and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.
|
| 09/18/2026 5:33 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/15/2026 9:24 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/15/2026 9:01 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/14/2026 6:36 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/11/2026 3:05 PM | AstraZeneca (901832) Issuer Sharma Mani (2122411) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/08/2026 8:04 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/08/2026 5:29 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/01/2026 11:08 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/01/2026 11:20 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/01/2026 6:27 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/01/2026 6:36 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/01/2026 6:10 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/01/2026 6:18 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/01/2026 6:04 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/27/2026 6:04 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/25/2026 6:03 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/19/2026 8:43 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/17/2026 6:08 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/17/2026 6:15 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/17/2026 6:03 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/07/2026 10:40 AM | AstraZeneca (901832) Issuer Sharma Mani (2122411) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/03/2026 9:44 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/03/2026 9:29 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/31/2026 5:54 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/14/2026 5:37 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/09/2026 5:17 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/08/2026 3:30 PM | AstraZeneca (901832) Issuer Sharma Mani (2122411) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/01/2026 9:10 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/01/2026 9:06 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/29/2026 1:30 PM | AstraZeneca (901832) Filer | Form 11-K Annual reports of employee stock purchase, savings and similar plans pursuant to Section 15(d) | |
The investigation Porter spent tens of thousands to document (Ad) Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film.
Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business. Watch the full investigation and decide for yourself |
| 06/29/2026 5:45 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/29/2026 5:05 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/16/2026 3:05 PM | AstraZeneca (901832) Issuer Sharma Mani (2122411) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/15/2026 5:52 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/01/2026 9:10 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/01/2026 9:06 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/29/2026 5:43 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/28/2026 1:29 PM | AstraZeneca (901832) Subject NEW YORK STOCK EXCHANGE LLC (876661) Filed by | Form 25-NSE | |
| 05/27/2026 5:04 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/26/2026 6:09 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/26/2026 6:17 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/26/2026 6:02 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/22/2026 3:05 PM | AstraZeneca (901832) Issuer Sharma Mani (2122411) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/18/2026 9:15 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/18/2026 8:42 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/18/2026 8:36 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/14/2026 6:25 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/08/2026 3:05 PM | AstraZeneca (901832) Issuer Sharma Mani (2122411) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/01/2026 9:23 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/01/2026 7:40 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/01/2026 7:45 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/29/2026 6:23 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/28/2026 10:32 AM | AstraZeneca (901832) Subject VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by | Form SCHEDULE 13G | |
| 04/28/2026 6:31 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/27/2026 5:29 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/23/2026 5:10 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/21/2026 5:19 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/20/2026 6:03 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/09/2026 12:01 PM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/08/2026 1:20 PM | AstraZeneca (901832) Subject NEW YORK STOCK EXCHANGE LLC (876661) Filed by | Form 25-NSE | |
| 04/02/2026 8:27 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/01/2026 9:30 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/31/2026 6:48 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/27/2026 7:04 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/20/2026 6:59 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/19/2026 6:51 PM | AstraZeneca (901832) Issuer Sharma Mani (2122411) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 03/16/2026 7:45 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/10/2026 7:07 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/10/2026 6:37 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/06/2026 7:11 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/06/2026 6:43 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/06/2026 6:50 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/04/2026 8:14 AM | AstraZeneca (901832) Filer | Form CERT | |
| 03/03/2026 3:01 PM | AstraZeneca Finance LLC (1862005) Filer AstraZeneca (901832) Filer | Form 8-A12B | |
| 03/02/2026 11:00 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/26/2026 7:59 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/25/2026 9:40 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/25/2026 7:30 AM | AstraZeneca Finance LLC (1862005) Filer AstraZeneca (901832) Filer | Form 424B2 Transaction specifc information for a delayed shelf offering | |
| 02/24/2026 5:51 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/24/2026 5:45 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Trump’s Plan To Cheat History (Ad) China has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and payment networks that bypass the dollar entirely.
Since the Federal Reserve opened in 1913, the dollar has lost most of its purchasing power. Porter Stansberry argues a new monetary order is forming around AI infrastructure, chips and energy, pointing to stocks like Vertiv, GE Vernova and Arista Networks that have surged hundreds of percent in recent years. Watch Porter Stansberry's full interview and see his top pick now |
| 02/20/2026 5:57 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/10/2026 10:55 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/06/2026 8:48 AM | AstraZeneca (901832) Filed by Innate Pharma SA (1598599) Subject Innate Pharma SA (1598599) Subject | Form SCHEDULE 13D/A | |
| 02/06/2026 8:54 AM | AstraZeneca (901832) Filed by Monopar Therapeutics (1645469) Subject | Form SCHEDULE 13G/A | |
| 02/03/2026 2:21 PM | AstraZeneca (901832) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 02/03/2026 6:01 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/02/2026 12:26 PM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/02/2026 6:51 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/02/2026 6:25 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |